ACRV – acrivon therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at Wall St
Acrivon Therapeutics (NASDAQ:ACRV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Form 4 Acrivon Therapeutics, For: Jan 14 Filed by: Blume-Jensen Peter
Form 4 Acrivon Therapeutics, For: Jan 14 Filed by: Levy Adam D.
Form 4 Acrivon Therapeutics, For: Jan 13 Filed by: Devroe Eric
Form 8-K Acrivon Therapeutics, For: Jan 08
Form 8-K Acrivon Therapeutics, For: Jan 08
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.